The EPP patients receiving the melanotan 1 implant experienced significantly less pain from phototoxicity, half as many phototoxic reactions, and an improvement in quality of life, compared to placebo [9]
Semaglutide is a GLP-1 receptor agonist medication that offers promising effects in helping to reduce body weight and lower blood sugar levels
GLP-1 Support is not designed to eliminate hunger or make you forget to eat
#HealthTech #Biotech #GLP1 #Tirzepatide#PharmaNews #Incretins #WeightManagement #DiabetesCare #FutureOfMedicine #Retatrutide #Pharmacology #Endocrinology #Biotechnology #ClinicalTrials #ObesityMedicine #Pharmaceuticals To view or add a comment, sign in Why does Lilly continue to invest in obesity pipelines after Zepbound
It communicates along the gut-brain axis, signaling satiety, slowing digestion, and helping to balance blood sugar
It functions as a dual GLP-1 and GIP receptor agonist , offering: Enhanced insulin secretion Delayed gastric emptying Appetite suppression Improved glycemic control Tirzepatide demonstrated impressive clinical outcomes in the SURMOUNT and SURPASS trials, with average weight loss of 15-22.5% and substantial A1C reductions
